Bristol-Myers Squibb (BMY)
NYSE: BMY
· Real-Time Price · USD
47.15
-0.08 (-0.17%)
At close: Sep 10, 2025, 3:59 PM
47.08
-0.14%
Pre-market: Sep 11, 2025, 04:25 AM EDT
Bristol-Myers Squibb Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abecma Revenue | 87M | 103M | 105M | 124M | 95M | 82M | 100M | 93M | 132M | 147M | 125M | 107M | 89M | 67M | 69M | 71M | 24M | 314M | 297M | 342M | 308M | 300M | 2.03B | 1.93B | 2.04B | 1.93B | 1.71B | 1.58B | 1.65B | 1.51B | 1.36B | 1.23B | 1.18B | 1.1B | 948M | 884M | 777M | 734M | 602M | 466M | 437M | 355M | 281M | 216M | 171M | 106M | 112M | 375M | 12M | 22M |
| Abecma Revenue Growth | -15.53% | -1.90% | -15.32% | +30.53% | +15.85% | -18.00% | +7.53% | -29.55% | -10.20% | +17.60% | +16.82% | +20.22% | +32.84% | -2.90% | -2.82% | +195.83% | -92.36% | +5.72% | -13.16% | +11.04% | +2.67% | -85.25% | +5.50% | -5.58% | +6.08% | +12.90% | +8.12% | -4.42% | +9.56% | +10.49% | +10.63% | +4.76% | +6.81% | +16.14% | +7.24% | +13.77% | +5.86% | +21.93% | +29.18% | +6.64% | +23.10% | +26.33% | +30.09% | +26.32% | +61.32% | -5.36% | -70.13% | +3025.00% | -45.45% | n/a |
| Abraxane Revenue | 105M | 105M | 174M | 253M | 231M | 217M | 247M | 260M | 258M | 239M | 179M | 177M | 241M | 214M | 305M | 266M | 296M | 2.89B | 2.27B | 2.1B | 2.16B | 2.64B | 1.76B | 1.82B | 1.82B | 1.8B | 1.8B | 1.79B | 1.63B | 1.51B | 1.36B | 1.26B | 1.2B | 1.13B | 1.31B | 920M | 840M | 704M | 475M | 305M | 122M | 40M | 5M | 1M | 402M | 363M | 397M | 316M | 352M | 320M |
| Abraxane Revenue Growth | 0.00% | -39.66% | -31.23% | +9.52% | +6.45% | -12.15% | -5.00% | +0.78% | +7.95% | +33.52% | +1.13% | -26.56% | +12.62% | -29.84% | +14.66% | -10.14% | -89.74% | +27.19% | +8.31% | -3.14% | -18.10% | +49.80% | -2.97% | -0.33% | +1.22% | -0.17% | +0.61% | +10.20% | +7.68% | +11.02% | +7.59% | +5.86% | +6.03% | -13.97% | +42.39% | +9.52% | +19.32% | +48.21% | +55.74% | +150.00% | +205.00% | +700.00% | +400.00% | -99.75% | +10.74% | -8.56% | +25.63% | -10.23% | +10.00% | n/a |
| Breyanzi Revenue | 344M | 263M | 263M | 224M | 153M | 107M | 101M | 92M | 100M | 71M | 55M | 44M | 39M | 44M | 40M | 30M | 17M | 1.72B | 1.79B | 1.78B | 1.65B | 1.77B | 792M | 767M | 778M | 640M | 731M | 675M | 711M | 593M | 662M | 632M | 650M | 535M | 625M | 572M | 593M | 475M | 540M | 484M | 461M | 400M | 443M | 444M | 368M | 342M | 365M | 238M | 312M | 287M |
| Breyanzi Revenue Growth | +30.80% | 0.00% | +17.41% | +46.41% | +42.99% | +5.94% | +9.78% | -8.00% | +40.85% | +29.09% | +25.00% | +12.82% | -11.36% | +10.00% | +33.33% | +76.47% | -99.01% | -4.07% | +0.73% | +7.68% | -6.40% | +122.98% | +3.26% | -1.41% | +21.56% | -12.45% | +8.30% | -5.06% | +19.90% | -10.42% | +4.75% | -2.77% | +21.50% | -14.40% | +9.27% | -3.54% | +24.84% | -12.04% | +11.57% | +4.99% | +15.25% | -9.71% | -0.23% | +20.65% | +7.60% | -6.30% | +53.36% | -23.72% | +8.71% | n/a |
| Camzyos Revenue | 260M | 159M | 223M | 156M | 139M | 84M | 88M | 68M | 46M | 29M | 16M | 5M | 3M | 3.21B | 2.67B | 2.41B | 2.79B | 758M | 867M | 826M | 750M | 714M | 549M | 558M | 544M | 459M | 536M | 382M | 421M | 405M | 527M | 509M | 506M | 463M | 494M | 472M | 451M | 407M | 429M | 411M | 405M | 375M | 398M | 385M | 321M | 271M | 260M | n/a | 233M | 229M |
| Camzyos Revenue Growth | +63.52% | -28.70% | +42.95% | +12.23% | +65.48% | -4.55% | +29.41% | +47.83% | +58.62% | +81.25% | +220.00% | +66.67% | -99.91% | +20.22% | +10.69% | -13.57% | +268.34% | -12.57% | +4.96% | +10.13% | +5.04% | +30.05% | -1.61% | +2.57% | +18.52% | -14.37% | +40.31% | -9.26% | +3.95% | -23.15% | +3.54% | +0.59% | +9.29% | -6.28% | +4.66% | +4.66% | +10.81% | -5.13% | +4.38% | +1.48% | +8.00% | -5.78% | +3.38% | +19.94% | +18.45% | +4.23% | n/a | n/a | +1.75% | n/a |
| Cobenfy Revenue | 35M | 27M | 3.19B | 3B | 3.42B | 3.72B | 2.87B | 2.71B | 3.2B | 3.42B | 2.69B | 2.65B | 3.23B | 1.92B | 1.99B | 1.91B | 1.91B | 773M | 835M | 777M | 745M | 713M | 385M | 353M | 367M | 384M | 384M | 491M | 535M | 438M | 269M | 323M | 322M | 330M | 264M | 285M | 241M | 263M | 265M | 240M | 296M | 325M | 366M | 350M | n/a | n/a | n/a | n/a | n/a | n/a |
| Cobenfy Revenue Growth | +29.63% | -99.15% | +6.43% | -12.12% | -8.17% | +29.44% | +6.25% | -15.57% | -6.40% | +27.34% | +1.24% | -17.93% | +68.23% | -3.27% | +4.36% | -0.26% | +147.09% | -7.43% | +7.46% | +4.30% | +4.49% | +85.19% | +9.07% | -3.81% | -4.43% | 0.00% | -21.79% | -8.22% | +22.15% | +62.83% | -16.72% | +0.31% | -2.42% | +25.00% | -7.37% | +18.26% | -8.37% | -0.75% | +10.42% | -18.92% | -8.92% | -11.20% | +4.57% | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Eliquis Revenue | 3.68B | 3.56B | 39M | 34M | 32M | 21M | 2.39B | 2.27B | 2.15B | 2.2B | 2.22B | 2.05B | 2.06B | 6M | 864M | 870M | 814M | 112M | 115M | 96M | 55M | 8M | n/a | n/a | n/a | n/a | n/a | 382M | 315M | 249M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Eliquis Revenue Growth | +3.23% | +9041.03% | +14.71% | +6.25% | +52.38% | -99.12% | +4.92% | +6.06% | -2.59% | -0.63% | +8.26% | -0.78% | +34283.33% | -99.31% | -0.69% | +6.88% | +626.79% | -2.61% | +19.79% | +74.55% | +587.50% | n/a | n/a | n/a | n/a | n/a | n/a | +21.27% | +26.51% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Krazati Revenue | 48M | 48M | 2.48B | 2.36B | 2.39B | 2.08B | 190M | 166M | 154M | 117M | 104M | 84M | 58M | 792M | 854M | 851M | 854M | 2.94B | 3.28B | 3.03B | 2.88B | 2.92B | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Krazati Revenue Growth | 0.00% | -98.06% | +5.04% | -1.13% | +14.87% | +993.68% | +14.46% | +7.79% | +31.62% | +12.50% | +23.81% | +44.83% | -92.68% | -7.26% | +0.35% | -0.35% | -70.99% | -10.24% | +8.36% | +4.96% | -1.06% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Opdivo Ovantig Revenue | 30M | 9M | 254M | 233M | 235M | 206M | 985M | 925M | 927M | 764M | 913M | 883M | 876M | 826M | 151M | 160M | 128M | 470M | 564M | 544M | 511M | 521M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Opdivo Ovantig Revenue Growth | +233.33% | -96.46% | +9.01% | -0.85% | +14.08% | -79.09% | +6.49% | -0.22% | +21.34% | -16.32% | +3.40% | +0.80% | +6.05% | +447.02% | -5.62% | +25.00% | -72.77% | -16.67% | +3.68% | +6.46% | -1.92% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Opdivo Revenue | 2.56B | 2.27B | 1B | 936M | 948M | 798M | 890M | 872M | 847M | 832M | 877M | 886M | 908M | 156M | 3.33B | 3.35B | 3.2B | 456M | 471M | 446M | 369M | 396M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Opdivo Revenue Growth | +13.02% | +126.50% | +6.84% | -1.27% | +18.80% | -10.34% | +2.06% | +2.95% | +1.80% | -5.13% | -1.02% | -2.42% | +482.05% | -95.31% | -0.57% | +4.53% | +602.19% | -3.18% | +5.61% | +20.87% | -6.82% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Opdualag Revenue | 284M | 252M | 512M | 433M | 341M | 319M | 320M | 248M | 234M | 206M | 199M | 190M | 172M | 2.8B | 555M | 551M | 541M | 18M | 9M | 2M | 1M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Opdualag Revenue Growth | +12.70% | -50.78% | +18.24% | +26.98% | +6.90% | -0.31% | +29.03% | +5.98% | +13.59% | +3.52% | +4.74% | +10.47% | -93.85% | +403.96% | +0.73% | +1.85% | +2905.56% | +100.00% | +350.00% | +100.00% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Orencia Revenue | 963M | 770M | 250M | 225M | 222M | 228M | 1.45B | 1.43B | 1.47B | 1.75B | 2.26B | 2.42B | 2.5B | 483M | 545M | 515M | 510M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Orencia Revenue Growth | +25.06% | +208.00% | +11.11% | +1.35% | -2.63% | -84.28% | +1.47% | -2.66% | -16.11% | -22.57% | -6.61% | -3.24% | +417.81% | -11.38% | +5.83% | +0.98% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Growth Brands Revenue | 470M | 403M | 823M | 898M | 959M | 865M | 63M | 66M | 25M | 16M | 7M | 1M | 544M | 515M | 48M | 40M | 28M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Growth Brands Revenue Growth | +16.63% | -51.03% | -8.35% | -6.36% | +10.87% | +1273.02% | -4.55% | +164.00% | +56.25% | +128.57% | +600.00% | -99.82% | +5.63% | +972.92% | +20.00% | +42.86% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Legacy Brands Revenue | 223M | 199M | 547M | 447M | 425M | 354M | 526M | 517M | 458M | 429M | 578M | 560M | 525M | 36M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Legacy Brands Revenue Growth | +12.06% | -63.62% | +22.37% | +5.18% | +20.06% | -32.70% | +1.74% | +12.88% | +6.76% | -25.78% | +3.21% | +6.67% | +1358.33% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pomalyst-Imnovid Revenue | 708M | 658M | 1.34B | 1.41B | 1.35B | 1.67B | 566M | 579M | 585M | 508M | 568M | 523M | 66M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pomalyst-Imnovid Revenue Growth | +7.60% | -50.86% | -5.17% | +4.36% | -18.93% | +194.88% | -2.25% | -1.03% | +15.16% | -10.56% | +8.60% | +692.42% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Reblozyl Revenue | 568M | 478M | 83M | 66M | 53M | 44M | 133M | 123M | 100M | 78M | 79M | 69M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Reblozyl Revenue Growth | +18.83% | +475.90% | +25.76% | +24.53% | +20.45% | -66.92% | +8.13% | +23.00% | +28.21% | -1.27% | +14.49% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Revlimid Revenue | 838M | 936M | 198M | 290M | 424M | 374M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Revlimid Revenue Growth | -10.47% | +372.73% | -31.72% | -31.60% | +13.37% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Sotyktu Revenue | 70M | 55M | 675M | 642M | 630M | 583M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Sotyktu Revenue Growth | +27.27% | -91.85% | +5.14% | +1.90% | +8.06% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Sprycel Revenue | 120M | 175M | 158M | 147M | 151M | 110M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Sprycel Revenue Growth | -31.43% | +10.76% | +7.48% | -2.65% | +37.27% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Yervoy Revenue | 728M | 624M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Yervoy Revenue Growth | +16.67% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Zeposia Revenue | 150M | 107M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Zeposia Revenue Growth | +40.19% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other Region Revenue | 270M | 3.11B | 350M | 3.39B | 3.22B | 3.19B | 3.29B | 3.15B | 3.16B | 3.15B | 200M | 3.06B | 3.43B | 227M | 221M | 276M | 191M | 164M | 162M | 184M | 172M | 113M | 166M | 114M | 127M | 117M | 146M | 159M | 143M | 136M |
| Other Region Revenue Growth | -91.32% | +788.57% | -89.67% | +5.12% | +1.07% | -3.04% | +4.35% | -0.22% | +0.35% | +1474.50% | -93.47% | -10.65% | +1409.69% | +2.71% | -19.93% | +44.50% | +16.46% | +1.23% | -11.96% | +6.98% | +52.21% | -31.93% | +45.61% | -10.24% | +8.55% | -19.86% | -8.18% | +11.19% | +5.15% | n/a |
| United States Revenue | 8.52B | 218M | 8.6B | 271M | 176M | 199M | 184M | 185M | 175M | 155M | 7.92B | 215M | 192M | 1.31B | 1.46B | 1.39B | 1.44B | 1.35B | 1.43B | 1.36B | 1.33B | 1.33B | 1.18B | 976M | 988M | 874M | 1B | 932M | 923M | 873M |
| United States Revenue Growth | +3807.80% | -97.46% | +3071.96% | +53.98% | -11.56% | +8.15% | -0.54% | +5.71% | +12.90% | -98.04% | +3586.05% | +11.98% | -85.39% | -10.00% | +4.96% | -3.07% | +6.61% | -5.68% | +4.85% | +2.02% | -0.07% | +13.62% | +20.39% | -1.21% | +13.04% | -13.03% | +7.83% | +0.98% | +5.73% | n/a |
| Rest Of World Revenue | 3.48B | 7.87B | 3.4B | 8.23B | 8.8B | 8.48B | 8B | 7.63B | 7.89B | 8.03B | n/a | 7.94B | 8.27B | 7.69B | 7.52B | 7.3B | 7.39B | 7.01B | 6.78B | 6.54B | 6.49B | 6.77B | 4.75B | 3.47B | 3.67B | 3.45B | 3.34B | 3.23B | 3.23B | 2.78B |
| Rest Of World Revenue Growth | -55.79% | +131.83% | -58.75% | -6.47% | +3.83% | +5.91% | +4.92% | -3.33% | -1.77% | n/a | n/a | -3.96% | +7.46% | +2.31% | +3.07% | -1.25% | +5.39% | +3.36% | +3.67% | +0.85% | -4.12% | +42.32% | +36.92% | -5.32% | +6.32% | +3.17% | +3.34% | +0.15% | +16.27% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 1.69B | 1.58B | 2.1B | 1.98B | 1.92B | 2.36B | 2.06B | 1.94B | 1.93B | 1.76B | 2.27B | 1.86B | 1.78B | 1.83B | 2.35B | 1.79B | 1.88B | 1.67B | 2.72B | 1.7B | 1.63B | 1.61B | 1.73B | 1.05B | 1.08B | 1B | 1.34B | 1.1B | 1.13B | 979M | 1.32B | 1.15B | 1.17B | 1.07B | 1.46B | 1.14B | 1.26B | 1.09B | 1.55B | 1.22B | 1.17B | 1.06B |
| Selling, General, and Administrative Revenue Growth | +6.82% | -24.80% | +6.53% | +2.81% | -18.59% | +14.39% | +6.50% | +0.52% | +9.42% | -22.24% | +22.02% | +4.15% | -2.52% | -22.24% | +31.62% | -5.05% | +12.90% | -38.67% | +59.88% | +4.49% | +1.31% | -6.95% | +63.60% | -1.95% | +7.06% | -24.83% | +21.21% | -2.48% | +15.53% | -25.61% | +14.73% | -1.71% | +8.66% | -26.49% | +27.71% | -9.42% | +15.87% | -29.68% | +26.63% | +4.53% | +10.89% | n/a |
| Research and Development Revenue | 2.26B | 2.24B | 2.79B | 2.35B | 2.29B | 2.69B | 2.48B | 2.18B | 2.26B | 2.3B | 2.51B | 2.36B | 2.32B | 2.22B | 2.61B | 3.25B | 3.27B | 2.22B | 2.79B | 2.5B | 2.48B | 2.32B | 1.99B | 1.36B | 1.31B | 1.3B | 1.36B | 1.26B | 2.42B | 1.23B | 1.41B | 1.48B | 1.09B | 1.02B | 1.21B | 1.14B | 1.27B | 1.14B | 1.92B | 1.13B | 1.86B | 1.02B |
| Research and Development Revenue Growth | +1.16% | -19.80% | +18.49% | +2.53% | -14.81% | +8.80% | +13.68% | -3.54% | -1.87% | -8.33% | +6.36% | +1.68% | +4.55% | -14.84% | -19.78% | -0.64% | +47.08% | -20.29% | +11.78% | +0.52% | +7.21% | +16.50% | +45.96% | +4.05% | +0.69% | -4.27% | +7.61% | -47.76% | +96.42% | -12.83% | -4.60% | +35.94% | +6.56% | -15.90% | +6.68% | -10.11% | +11.44% | -40.71% | +69.26% | -39.01% | +82.68% | n/a |